Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys

Autor(es):Mostrar menos -

Kessler, R. C. ^[1] ; Sampson, N. A. ^[1] ; Berglund, P. ^[2] ; Gruber, M. J. ^[1] ; Al-Hamzawi, A. ^[3] ; Andrade, L. ^[4] ; Bunting, B. ^[5] ; Demyttenaere, K. ^[6] ; Florescu, S. ^[7] ; de Girolamo, G. ^[8] ; Gureje, O. ^[9] ; He, Y. ^[10] ; Hu, C. ^{[11, 12]} ; Huang, Y. ^[13] ; Karam, E. ^{[14, 15, 16]} ; Kovess-Masfety, V. ^[17] ; Lee, S. ^[18] ; Levinson, D. ^[19] ; Medina Mora, M. E. ^[20] ; Moskalewicz, J. ^[21] ; Nakamura, Y. ^[22] ; Navarro-Mateu, F. ^[23] ; Browne, M. A. Oakley ^[24] ; Piazza, M. ^[25] ; Posada-Villa, J. ^[26] ; Slade, T. ^[27] ; ten Have, M. ^[28] ; Torres, Y. ^[29] ; Vilagut, G. ^[30] ; Xavier, M. ^{[31, 32]} ; Zarkov, Z. ^[33] ; Shahly, V. ^[1] ; Wilcox, M. A. ^[34]

Afiliação do(s) autor(es):Mostrar menos -

^[1] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 - USA

^[2] Univ Michigan, Inst Social Res, Ann Arbor, MI - USA

^[3] Al Qadisiya Univ, Coll Med, Diwania Governorate - Iraq

^[4] Univ Sao Paulo, Sch Med, Inst Psychiat, Sao Paulo - Brazil

^[5] Univ Ulster, Sch Psychol, Londonberry - Ireland

^[6] Katholieke Univ Leuven, Univ Hosp Gasthuisberg, Dept Psychiat, Leuven - Belgium

^[7] Natl Sch Publ Hlth Management & Profess Dev, Bucharest - Romania

^[8] IRCCS St John God Clin Res Ctr, Unit Epidemiol & Evaluat Psychiat, Brescia - Italy

^[9] Univ Ibadan, Dept Psychiat, Ctr Res & Training Mental Hlth Neurosci Drug & Al, Ibadan - Nigeria

^[10] Shanghai Jiao Tong Univ, Shanghai Mental Hlth Ctr, Sch Med, Shanghai 200030 - Peoples R China

^[11] Shenzhen Inst Mental Hlth, Shenzhen, Guangdong - Peoples R China

^[12] Shenzhen Kanging Hosp, Shenzhen, Guangdong - Peoples R China

^[13] Peking Univ, Inst Mental Hlth, Beijing 100871 - Peoples R China

^[14] Balamand Univ, Fac Med, Dept Psychiat & Clin Psychol, Beirut - Lebanon

^[15] St George Hosp Univ, Med Ctr, Dept Psychiat & Clin Psychol, Beirut - Lebanon

^[16] IDRAAC, Beirut - Lebanon

^[17] Paris Descartes Univ, EHESP, EA 4057, Paris - France

^[18] Chinese Univ Hong Kong, Dept Psychiat, Shatin, Hong Kong - Peoples R China

^[19] Minist Hlth Israel, Mental Hlth Serv, Jerusalem - Israel

^[20] Ramond e Fuente Muniz Natl Inst Psychiat, Mexico City, DF - Mexico

^[21] Inst Psychiat & Neurol, Warsaw - Poland

^[22] Jichi Med Univ, Dept Publ Hlth, Shimotsuke, Tochigi - Japan

^[23] CIBERESP Nodo, IMIB Arrixaca, Serv Murciano Salud, UDIF SM, Murcia - Spain

^[24] Univ Tasmania, Sch Med, Dept Psychiat, Hobart, Tas 7001 - Australia

^[25] Natl Inst Hlth, Lima - Peru

^[26] Univ Colegio Mayor Cundinamarca, Bogota - Colombia

^[27] Univ New S Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW - Australia

^[28] Netherlands Inst Mental Hlth & Addict, Utrecht - Netherlands

^[29] CES Univ, Ctr Excellence Res Mental Hlth, Medellin - Colombia

^[30] IMIM Inst Hosp Mar Invest Med, Hlth Serv Res Unit, Edifici PRBB, Barcelona 08003 - Spain

^[31] Univ Nova Lisboa, Dept Mental Hlth CEDOC, P-1200 Lisbon - Portugal

^[32] Univ Nova Lisboa, Fac Ciencias Med, P-1200 Lisbon - Portugal

^[33] NCPHA, Dept Mental Hlth, Sofia - Bulgaria

^[34] Janssen Pharmaceut Res & Dev, Titusville, NJ - USA

• Tipo de documento: Artigo Científico
• Fonte: EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES; v. 24, n. 3, p. 210-226, JUN 2015.
• Citações Web of Science: 66

Resumo

Background. To examine cross-national patterns and correlates of lifetime and 12-month comorbid DSM-IV anxiety disorders among people with lifetime and 12-month DSM-IV major depressive disorder (MDD). Method. Nationally or regionally representative epidemiological interviews were administered to 74045 adults in 27 surveys across 24 countries in the WHO World Mental Health (WMH) Surveys. DSM-IV MDD, a wide range of comorbid DSM-IV anxiety disorders, and a number of correlates were assessed with the WHO Composite International Diagnostic Interview (CIDI). Results. 45.7% of respondents with lifetime MDD (32.0-46.5% inter-quartile range (IQR) across surveys) had one of more lifetime anxiety disorders. A slightly higher proportion of respondents with 12-month MDD had lifetime anxiety disorders (51.7%, 37.8-54.0% IQR) and only slightly lower proportions of respondents with 12-month MDD had 12-month anxiety disorders (41.6%, 29.9-47.2% IQR). Two-thirds (68%) of respondents with lifetime comorbid anxiety disorders and MDD reported an earlier age-of-onset (AOO) of their first anxiety disorder than their MDD, while 13.5% reported an earlier AOO of MDD and the remaining 18.5% reported the same AOO of both disorders. Women and previously married people had consistently elevated rates of lifetime and 12-month MDD as well as comorbid anxiety disorders. Consistently higher proportions of respondents with 12-month anxious than non-anxious MDD reported severe role impairment (64.4 v. 46.0%; chi(2)(1)=187.0, p<0.001) and suicide ideation (19.5 v. 8.9%;chi(2)(1)=71.6, p<0.001). Significantly more respondents with 12-month anxious than non-anxious MDD received treatment for their depression in the 12 months before interview, but this difference was more pronounced in high-income countries (68.8 v. 45.4%; chi(2)(1)=108.8, p<0.001) than low/middle-income countries (30.3 v. 20.6%; chi(2)(1)=11.7, p<0.001). Conclusions. Patterns and correlates of comorbid DSM-IV anxiety disorders among people with DSM-IV MDD are similar across WMH countries. The narrow IQR of the proportion of respondents with temporally prior AOO of anxiety disorders than comorbid MDD (69.6-74.7%) is especially noteworthy. However, the fact that these proportions are not higher among respondents with 12-month than lifetime comorbidity means that temporal priority between lifetime anxiety disorders and MDD is not related to MDD persistence among people with anxious MDD. This, in turn, raises complex questions about the relative importance of temporally primary anxiety disorders as risk markers v. causal risk factors for subsequent MDD onset and persistence, including the possibility that anxiety disorders might primarily be risk markers for MDD onset and causal risk factors for MDD persistence. (AU)

• Processo FAPESP: 03/00204-3 - Estudo epidemiológico dos transtornos psiquiátricos na região metropolitana de São Paulo: prevalências, fatores de risco e sobrecarga social e econômica
• Beneficiário: Laura Helena Silveira Guerra de Andrade
• Modalidade de apoio: Auxílio à Pesquisa - Temático